New Drug Causes 20 Percent Weigh Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Amgen Crashes 9% Despite 'Truly Remarkable' Results For Obesity Treatment
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.
Amgen stock was dropping in premarket trading after releasing what looked like positive data from a Phase 2 study for its ...
Wall Street Journal on MSN54m
Amgen Obesity Drug Cut Weight In Closely Watched Study
A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...
Pacbiztimes.com50m
Amgen’s shares down after obesity drug fails to meet expectations
MarTide, the new weight loss drug from Amgen, works. Not just well enough for Wall Street. Shares of the Thousand Oaks-based biotech giant fell 10% on Nov. 26 after it announced that MarTide's latest ...
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...
btimesonline50m
Amgen’s MariTide Shows Promise With 20% Weight Loss, Yet Shares Dip 10%
Amgen Inc. announced on Tuesday that its experimental weight-loss drug, MariTide, demonstrated an average weight reduction of ...
Investopedia on MSN50m
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs
Congress. "Hearings to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity." The White House. "FACT SHEET: Biden-⁠Harris Administration Takes Latest Step ...